Humacyte (HUMA) Projected to Announce Quarterly Earnings on Monday

Humacyte (NASDAQ:HUMA) is projected to post its Q2 2026 results before the market opens on Monday, August 10th. Analysts expect the company to announce earnings of ($0.10) per share and revenue of $1.1190 million for the quarter. Investors may review the information on the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Friday, August 14, 2026 at 12:30 PM ET.

Humacyte (NASDAQ:HUMA) last announced its earnings results on Wednesday, May 13th. The company reported ($0.09) earnings per share for the quarter, beating the consensus estimate of ($0.10) by $0.01. The business had revenue of $0.49 million during the quarter, compared to the consensus estimate of $1.46 million. Humacyte had a negative net margin of 4,836.06% and a negative return on equity of 2,914.18%. On average, analysts expect Humacyte to post $-0 EPS for the current fiscal year and $-0 EPS for the next fiscal year.

Humacyte Price Performance

HUMA opened at $0.65 on Monday. Humacyte has a twelve month low of $0.55 and a twelve month high of $2.76. The firm has a market cap of $144.34 million, a price-to-earnings ratio of -1.14 and a beta of 2.54. The company has a current ratio of 3.93, a quick ratio of 3.32 and a debt-to-equity ratio of 5.46. The company has a fifty day simple moving average of $0.90 and a 200 day simple moving average of $0.93.

Insider Transactions at Humacyte

In other news, CFO Dale A. Sander sold 45,887 shares of the business’s stock in a transaction dated Monday, May 18th. The shares were sold at an average price of $0.90, for a total value of $41,298.30. Following the completion of the sale, the chief financial officer owned 267,213 shares of the company’s stock, valued at approximately $240,491.70. The trade was a 14.66% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Kathleen Sebelius purchased 56,818 shares of Humacyte stock in a transaction dated Tuesday, May 19th. The shares were bought at an average cost of $0.88 per share, for a total transaction of $49,999.84. Following the transaction, the director directly owned 148,025 shares of the company’s stock, valued at approximately $130,262. The trade was a 62.30% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders own 3.10% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of HUMA. Atom Investors LP acquired a new position in shares of Humacyte in the 4th quarter worth approximately $25,000. Financial Advisors Network Inc. acquired a new stake in shares of Humacyte during the 2nd quarter valued at approximately $28,000. Prudential Financial Inc. bought a new position in Humacyte during the second quarter worth $28,000. Equitable Holdings Inc. bought a new position in Humacyte during the third quarter worth $29,000. Finally, Imprint Wealth LLC acquired a new position in Humacyte in the third quarter worth $33,000. Institutional investors own 44.71% of the company’s stock.

Analysts Set New Price Targets

Several analysts have recently weighed in on HUMA shares. D. Boral Capital restated a “buy” rating and set a $25.00 target price on shares of Humacyte in a research note on Tuesday, April 28th. HC Wainwright boosted their price target on Humacyte from $3.00 to $4.00 and gave the stock a “buy” rating in a research note on Thursday, June 11th. BTIG Research reissued a “buy” rating and issued a $2.00 price target on shares of Humacyte in a report on Tuesday, July 28th. Weiss Ratings restated a “sell (e+)” rating on shares of Humacyte in a research note on Wednesday, July 8th. Finally, Benchmark lifted their price objective on Humacyte to $2.00 and gave the stock a “speculative buy” rating in a report on Monday, June 1st. Seven investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $6.25.

Humacyte Company Profile

Humacyte, Inc is a clinical-stage biotechnology company focused on the development and manufacturing of off-the-shelf, regenerative human acellular vessels (HAVs) designed to address critical vascular access needs. The company’s proprietary vessels are engineered from human donor cells and then decellularized to create a biocompatible scaffold capable of integrating with a patient’s own tissue. Humacyte’s primary business activities encompass process development, large-scale manufacturing, and clinical evaluation of HAVs for use in end-stage renal disease, peripheral arterial disease and other vascular repair applications.

The company’s lead product candidate, the HAV, has advanced through multiple clinical trials for arteriovenous access in hemodialysis patients, demonstrating durability, reduced infection rates and compatibility with repeated cannulation.